Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience - Top-Institutions - MDSpire

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience

  • By

  • Sara A. Scott

  • Ellen M. Marin

  • Kathryn T. Maples

  • Nisha S. Joseph

  • Craig C. Hofmeister

  • Vikas A. Gupta

  • Madhav V. Dhodapkar

  • Jonathan L. Kaufman

  • Sagar Lonial

  • Ajay K. Nooka

  • December 20, 2023

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #4

    Emory University Hospital
    Emory University Hospital

    Atlanta, GA

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy

  • #5

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy

Original Source(s)

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience

  • by Sara A. Scott, Ellen M. Marin, Kathryn T. Maples, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka

  • December 20, 2023

Related Content

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min
Not all plasma cells are made equal: well-hidden layers of heterogeneity

Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders